LINC01232

Across TCGA pan-cancer cohorts, LINC01232 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of LINC01232’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where LINC01232 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01232 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

BLCA, COAD, and HNSC are the cancer types where LINC01232 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01232 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	All	+1.622	<.001	11	view →
COAD	Male	III,IV	+1.232	<.001	11	view →
HNSC	Male	All	+0.973	<.001	11	view →
KIRC	All	IV	+0.708	<.001	10	view →
THCA	Male	All	−0.310	<.001	9	view →
STAD	Male	II,III,IV	+1.128	<.001	8	view →
LUAD	Female	All	+0.565	<.001	8	view →
READ	All	All	+0.921	<.001	7	view →
UCEC	All	III,IV	+0.490	.005	6	view →
KIRP	All	All	+0.313	<.001	6	view →
LUSC	Male	All	+0.739	<.001	5	view →
LIHC	Male	All	+0.474	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

LINC01232–BLCA

Open the BLCA breakdown →